Oral Anti-Cancer Therapy Pomalidomide Celgene International Sárl (CELG) Receives Positive CHMP Opinion as Treatment for Patients With Relapsed and Refractory Multiple Myeloma
5/31/2013 1:14:05 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by